{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PD-0325901", "query": { "intervention": "PD-0325901" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PD-0325901&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T12:16:55.283Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03905148", "title": "Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "Lifirafenib", "type": "DRUG" }, { "name": "mirdametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2019-05-01", "completion_date": "2025-10-23", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-09-02T12:16:55.283Z", "location_count": 2, "location_summary": "Santa Monica, California • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03905148" }, { "nct_id": "NCT05580770", "title": "Mirdametinib + BGB-3245 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "Mirdametinib 2mg", "type": "DRUG" }, { "name": "BGB-3245 5mg", "type": "DRUG" }, { "name": "Mirdametinib 3mg", "type": "DRUG" }, { "name": "Mirdametinib 4mg", "type": "DRUG" }, { "name": "BGB-3245 10mg", "type": "DRUG" }, { "name": "BGB-3245 20mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2023-02-03", "completion_date": "2025-01-15", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-02T12:16:55.283Z", "location_count": 6, "location_summary": "La Jolla, California • New Haven, Connecticut • Boston, Massachusetts + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05580770" }, { "nct_id": "NCT06843967", "title": "A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Well Differentiated Liposarcoma", "Dedifferentiated Liposarcoma", "Liposarcoma", "Myxoid Liposarcoma", "Round Cell Liposarcoma", "Myxoid Pleomorphic Liposarcoma", "Pleomorphic Liposarcoma", "Unresectable Liposarcoma", "Unresectable Dedifferentiated Liposarcoma" ], "interventions": [ { "name": "Mirdametinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2025-02-19", "completion_date": "2028-08-19", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-02T12:16:55.283Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06843967" }, { "nct_id": "NCT01347866", "title": "Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "PF-05212384", "type": "DRUG" }, { "name": "PD-0325901", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2011-10", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2018-10-29", "last_synced_at": "2026-09-02T12:16:55.283Z", "location_count": 15, "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01347866" }, { "nct_id": "NCT06997276", "title": "Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Hepatic Impairment" ], "interventions": [ { "name": "Mirdametinib (MEK Inhibitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 32, "start_date": "2025-05-07", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-02T12:16:55.283Z", "location_count": 3, "location_summary": "Miami, Florida • Orlando, Florida • San Antonio, Texas", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06997276" }, { "nct_id": "NCT04923126", "title": "SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Low-Grade Glioma", "Recurrent Low-Grade Glioma", "Progressive Low-Grade Glioma" ], "interventions": [ { "name": "Mirdametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "2 Years to 24 Years" }, "enrollment_count": 132, "start_date": "2021-06-21", "completion_date": "2031-06", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-09-02T12:16:55.283Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04923126" }, { "nct_id": "NCT02096471", "title": "MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN" ], "interventions": [ { "name": "PD-0325901", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 19, "start_date": "2014-06", "completion_date": "2018-08-01", "has_results": true, "last_update_posted_date": "2019-01-10", "last_synced_at": "2026-09-02T12:16:55.283Z", "location_count": 11, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02096471" }, { "nct_id": "NCT07237100", "title": "Mirdametinib in Patients With Advanced NF1-mutant Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Unresectable Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "Mirdametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kevin Kim, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2025-10-13", "completion_date": "2030-10-13", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-09-02T12:16:55.283Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07237100" }, { "nct_id": "NCT07061951", "title": "Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Mirdametinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-05-27", "completion_date": "2030-02-01", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-02T12:16:55.283Z", "location_count": 8, "location_summary": "Duarte, California • Irvine, California • Sacramento, California + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07061951" }, { "nct_id": "NCT03962543", "title": "MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plexiform Neurofibroma", "Neurofibromatosis Type 1 (NF1)" ], "interventions": [ { "name": "Mirdametinib (PD-0325901) oral capsule or dispersible tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 114, "start_date": "2019-09-29", "completion_date": "2028-12-22", "has_results": true, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-02T12:16:55.283Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03962543" } ] }